Desidustat in Renal Disease: Considerations for Use

Dosing and Monitoring

• The Kidney International guideline recommends dose adjustments for desidustat based on hemoglobin response, with the goal of maintaining hemoglobin levels between 10-12 g/dL 1
• Treatment with desidustat should be temporarily discontinued if hemoglobin levels exceed 12 or 13 g/dL, following protocols similar to other HIF-PHIs 1
• Lower starting doses of desidustat should be considered for ESA-naïve patients compared to those transitioning from other ESAs 1
• Regular monitoring of hemoglobin levels is necessary to maintain a target range of 10-12 g/dL 2
• Consider discontinuation of desidustat if hemoglobin targets are not achieved despite dose escalation 1

Special Population Considerations

• Desidustat should not be used in patients with polycystic kidney disease until adequate safety data emerge, as HIF activation may potentially enhance cyst expansion based on preclinical models 3
• Desidustat is not recommended for use in pediatric CKD patients, as patients under 18 years were excluded from clinical trials 3
• Caution is advised in kidney transplant recipients due to limited data and potential concerns about HIF-PHIs affecting immune cell function 3
• Desidustat should not be used when the anticipated treatment outcome is cure, including with primary and adjuvant chemotherapy for potentially curable malignancies 4

Safety and Efficacy

• Oral administration of desidustat provides convenience over injectable ESAs, particularly beneficial for non-dialysis and peritoneal dialysis patients 5
• Unlike some other HIF-PHIs, specific cardiovascular safety data for desidustat in large outcomes trials is limited compared to agents like roxadustat, vadadustat, and daprodustat 1
• The pleiotropic effects of HIF activation beyond erythropoiesis must be considered when evaluating long-term safety 5
• Potential drug-drug interactions should be evaluated when desidustat is used with other oral medications 3

Desidustat for Anemia in Chronic Kidney Disease

Efficacy Profile

• The KDIGO consensus confirms that desidustat, along with other HIF-PHIs, is superior to placebo and non-inferior to ESAs in increasing and maintaining hemoglobin concentration 6, 7, 8

Safety Considerations

• Desidustat has a favorable safety profile with predominantly mild adverse events, though long-term cardiovascular safety data are more limited compared to other HIF-PHIs like roxadustat, vadadustat, and daprodustat 6

Clinical Advantages Over ESAs

• The oral route of administration provides significant practical advantages over injectable ESAs, particularly for non-dialysis and peritoneal dialysis patients, and avoids the high peak serum EPO concentrations seen with injectable ESAs, potentially reducing cardiovascular risks 9

Hemoglobin Targets

• Target hemoglobin levels of 10-12 g/dL should be maintained with desidustat, consistent with current guideline recommendations for ESAs, and available data do not support targeting higher hemoglobin levels with HIF-PHIs than the currently recommended targets established with ESAs 6, 7, 8

Desidustat Use in CKD‑Associated Anemia – Evidence‑Based Guideline Summary

Contraindications and Cautions

• A history of stroke warrants caution when prescribing desidustat because of potential increased vascular risk. 10
• Prior malignancy requires great caution with desidustat therapy due to theoretical concerns about HIF‑mediated tumor promotion. 10

Monitoring Recommendations

Hemoglobin Monitoring

• For non‑dialysis CKD patients on maintenance desidustat, check hemoglobin at least every 3 months. 11
• For dialysis‑dependent patients, perform monthly hemoglobin assessments. 11
• Increase monitoring frequency during therapy initiation, dose escalation, or after any episode of blood loss. 11

Iron Status Monitoring

• Measure transferrin saturation (TSAT) and ferritin at least every 3 months while on desidustat. 11
• Conduct more frequent iron studies when starting or increasing desidustat, after bleeding events, or when evaluating response to iron therapy. 11

Iron Supplementation (First‑Line Therapy)

• Initiate a trial of intravenous iron (or a 1–3 month oral iron course for non‑dialysis patients) when TSAT ≤ 30 % and ferritin ≤ 500 ng/mL. 11

Alternative Therapies

• Erythropoiesis‑stimulating agents (ESAs) such as erythropoietin and darbepoetin alfa remain the primary alternatives to desidustat, with iron supplementation required before any ESA use. 12
• Red blood cell transfusions are indicated for patients with hemoglobinopathies, bone‑marrow failure, or ESA resistance. 12
• Transfusions should be minimized in transplant‑eligible patients to reduce allo‑sensitization risk. 13

Hemoglobin Target Guidance

• Intentionally raising hemoglobin above 13 g/dL should be avoided; large trials have linked higher levels to increased cardiovascular events, stroke, and mortality. 10
• In general, maintain hemoglobin below 11.5 g/dL in adult CKD patients, with individualization as needed for quality‑of‑life considerations. 10

Safety Profile of Other HIF‑PHIs

• Roxadustat, vadadustat, and daprodustat possess more extensive cardiovascular safety data from large phase 3 programs compared with desidustat. [14][15]16

Potential Vascular and Non‑Erythropoietic Effects of Desidustat

Vascular and Cardiovascular Risk Considerations

• Preclinical evidence shows that desidustat’s activation of hypoxia‑inducible factor pathways can influence vascular homeostasis, hemodynamics, inflammation, and cellular metabolism, potentially modifying the risk of cardiovascular disease, thrombosis, and malignancy in patients with chronic kidney disease. 17

Uncertainty of Non‑Erythropoietic Pathway Activation

• The extent to which desidustat stimulates non‑erythropoietic signaling pathways in treated individuals remains difficult to predict and quantify, indicating a current limitation in mechanistic knowledge. 17